Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)
- Citation:
- Cancer vol 115 (1) 84-93
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA047577, U10 CA032291, CA33601, CA04457, U10 CA031946-25, CA11789, U10 CA077658, CA02599, CA47577, CA47555, CA35113, CA32291, CA29165, CA41287, CA03927, U10 CA031946, U10 CA033601, CA35199, CA12046, CA16450, U10 CA004326, U10 CA041287, U10 CA035113, U10 CA047559, CA04326, CA74811, CA21060, CA47559, CA47642, U10 CA074811, CA77658, CA12449, U10 CA047642, CA31983, CA31946, U10 CA003927, CA07968
- Corr. Author:
- Authors:
- David L. Grinblatt Daohai Yu Vera Hars James W. Vardiman Bayard L. Powell Sreenivasa Nattam Lewis R. Silverman Carlos de Castro Richard M. Stone Clara D. Bloomfield Richard A. Larson
- Networks:
- Study
- CALGB-19803
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Article